ClinicalTrials.gg
CompletedNCT00471146Updated Jul 16, 2012Results posted

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

A Phase 3 interventional study of AG-013736 and Gemcitabine in Carcinoma, Pancreatic Ductal, sponsored by Pfizer. Completed at 205 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Carcinoma, Pancreatic Ductal with a site in United States — 5 open to participants now, 10 under way, 1 of them phase 3. Carcinoma, Pancreatic Ductal · United States.

Enrollment
4th of 26
630 · median 97
Started
2007
the only one that year
Phase 3
4 of 30
none open now
Registered
2nd of 30
by date
Lead sponsor
4 of 30
Pfizer

Among the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2007, is one of 4 in phase 3, and was the 2nd registered.

Carcinoma, Pancreatic Ductal

57 studies on the registry are indexed under Carcinoma, Pancreatic Ductal; 10 are open to participants now.

Browse Carcinoma, Pancreatic Ductal studies →

Open to participants now

5 of the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Carcinoma, Pancreatic Ductal studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.

Read the detailed description

This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.

03

Conditions studied

  • Carcinoma, Pancreatic Ductal

Keywords

  • Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed, or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection.
  • Adequate renal, hepatic and bone marrow function.
  • Performance status 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any systemic chemotherapy for disease.
  • Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors.
  • Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.
  • Inability to take oral medication.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
630 participants (actual)

Study arms

  • Experimental
    A

    Drug: AG-013736 · Drug: Gemcitabine

  • Active comparator
    B

    Drug: Gemcitabine · Drug: placebo

Interventions

  • oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.

  • intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.

  • intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time in weeks from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death or at least 1 year after the randomization of last participant

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline until disease progression or at least 1 year after the randomization of last participant

  2. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

    Time frame: Baseline, every 8 weeks until tumor progression or death

  3. Duration of Response (DR)

    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.

    Time frame: Baseline until death or at least 1 year after the randomization of last participant

  4. Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

    Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal

  5. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score

    QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.

    Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal

  6. Change From Baseline Brief Pain Inventory-short Form (BPI-sf) Score

    BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.

    Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal

  7. Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal

  8. Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal

  9. Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 23 months

07

Results

Posted Jul 16, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + GemcitabinePlacebo + Gemcitabine
Started314316
Treated305308
Completed142142
Not completed172174
Withdrew: Adverse event3233
Withdrew: Withdrawal by subject1411
Withdrew: Death1112
Withdrew: Lost to follow-up42
Withdrew: Protocol violation22
Withdrew: Objective progression or relapse8487
Withdrew: Global deterioration of health status1214
Withdrew: Randomized but not treated98
Withdrew: Other45

Outcome measures

PrimaryOverall Survival (OS)

Time in weeks from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death or at least 1 year after the randomization of last participant
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksAxitinib + GemcitabinePlacebo + Gemcitabine
Overall Survival (OS)36.9 (30.1 to 41.1)35.8 (30.0 to 44.8)
Statistical analysis
  • Axitinib + Gemcitabine vs Placebo + Gemcitabine · Log Rank · p = 0.5436 (One-sided log-rank test at alpha = 0.025 significance level was used.) · Hazard ratio (hr): 1.014 · 95% CI 0.786 to 1.309
SecondaryProgression Free Survival (PFS)

Time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline until disease progression or at least 1 year after the randomization of last participant
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksAxitinib + GemcitabinePlacebo + Gemcitabine
Progression Free Survival (PFS)19.1 (17.1 to 24.4)18.9 (16.2 to 22.6)
Statistical analysis
  • Axitinib + Gemcitabine vs Placebo + Gemcitabine · Log Rank · p = 0.5203 (One-sided log-rank test at alpha = 0.025 significance level was used.The p-value was not adjusted for multiple testing.) · Hazard ratio (hr): 1.006 · 95% CI 0.779 to 1.298
SecondaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

Time frame:
Baseline, every 8 weeks until tumor progression or death
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib + GemcitabinePlacebo + Gemcitabine
Percentage of Participants With Objective Response (OR)4.9 (2.5 to 8.3)1.6 (0.4 to 4.0)
Statistical analysis
  • Axitinib + Gemcitabine vs Placebo + Gemcitabine · Cochran-Mantel-Haenszel · p = 0.038 · Risk ratio (rr): 3.2 · 95% CI 1.0 to 10.1
SecondaryDuration of Response (DR)

Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.

Time frame:
Baseline until death or at least 1 year after the randomization of last participant
Reported as:
Median · Weeks
Duration of Response (DR)
WeeksAxitinib + GemcitabinePlacebo + Gemcitabine
Duration of Response (DR)33.1 (16.1 to 33.1)NA (NA to NA)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

Time frame:
Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score
Units on a scaleAxitinib + GemcitabinePlacebo + Gemcitabine
Physical functioning: Baseline (n=295, 289)77.445 ± 20.305278.546 ± 18.9192
Physical functioning: Change at C2 D1 (n=233, 233)-2.713 ± 16.7682-3.261 ± 15.0742
Physical functioning: Change at C3 D1 (n=173, 179)-5.897 ± 19.3522-1.565 ± 16.2738
Physical functioning: Change at C4 D1 (n=134, 133)-5.671 ± 18.8623-1.453 ± 17.1209
Physical functioning: Change at C5 D1 (n=96, 82)-2.498 ± 21.8687-0.076 ± 16.9709
Physical functioning: Change at C6 D1 (n=59, 58)-5.193 ± 19.6995-1.719 ± 15.5260
Physical functioning: Change at C7 D1 (n=38, 37)-1.924 ± 14.27260.011 ± 18.9261
Physical functioning: Change at C8 D1 (n=15, 21)-4.000 ± 16.87590.014 ± 13.8428
Physical functioning: Change at C9 D1 (n=9, 9)0.033 ± 15.2534-12.578 ± 20.9490
Physical functioning: Change at C10 D1 (n=3, 4)6.667 ± 17.5754-1.675 ± 22.0563
Physical functioning: Change at C11 D1 (n=1, 1)0.000 ± NA-6.600 ± NA
Physical functioning: Change at C12 D1 (n=1, 0)0.000 ± NANA ± NA
Physical functioning: Change at C13 D1 (n=1, 0)0.000 ± NANA ± NA
Physical functioning:Change at followup (n=67, 70)-17.713 ± 23.8263-11.523 ± 21.0513
Role functioning: Baseline (n=297, 295)66.3 ± 30.0968.1 ± 30.72
Role functioning: Change at C2 D1 (n=239, 242)-2.2 ± 30.95-2.8 ± 25.75
Role functioning: Change at C3 D1 (n=177, 185)-4.6 ± 32.651.5 ± 26.90
Role functioning: Change at C4 D1 (n=135, 136)-4.3 ± 32.131.2 ± 27.18
Role functioning: Change at C5 D1 (n=99, 81)-0.5 ± 34.95-2.7 ± 29.63
Role functioning: Change at C6 D1 (n=60, 58)-4.4 ± 29.25-2.3 ± 24.27
Role functioning: Change at C7 D1 (n=38, 37)-3.1 ± 25.07-1.3 ± 26.75
Role functioning: Change at C8 D1 (n=16, 21)-6.2 ± 20.050.0 ± 31.63
Role functioning: Change at C9 D1 (n=9, 9)1.9 ± 28.21-20.4 ± 33.11
Role functioning: Change at C10 D1 (n=3, 4)5.6 ± 9.64-4.2 ± 28.46
Role functioning: Change at C11 D1 (n=1, 1)0.0 ± NA-50.0 ± NA
Role functioning: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Role functioning: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Role functioning: Change at follow-up (n=66, 72)-20.0 ± 31.52-14.1 ± 32.34
Emotional functioning (EF): Baseline (n=294, 287)70.8 ± 22.0171.7 ± 22.47
EF: Change at C2 D1 (n=233, 229)5.0 ± 21.485.0 ± 18.92
EF: Change at C3 D1 (n=170, 180)3.7 ± 20.193.4 ± 18.95
EF: Change at C4 D1 (n=134, 131)3.0 ± 22.545.2 ± 21.12
EF: Change at C5 D1 (n=96, 80)4.3 ± 21.095.9 ± 17.24
EF: Change at C6 D1 (n=60, 56)4.0 ± 19.316.7 ± 17.43
EF: Change at C7 D1 (n=37, 34)0.0 ± 18.843.2 ± 16.28
EF: Change at C8 D1 (n=17, 19)-2.9 ± 22.055.3 ± 14.74
EF: Change at C9 D1 (n=9, 9)3.7 ± 16.72-4.6 ± 15.07
EF: Change at C10 D1 (n=3, 4)13.9 ± 12.732.1 ± 18.50
EF: Change at C11 D1 (n=1, 1)0.0 ± NA-16.6 ± NA
EF: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
EF: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
EF: Change at follow-up (n=65, 71)-7.3 ± 23.51-2.7 ± 23.14
Cognitive Functioning (CF): Baseline (n=293, 288)78.7 ± 22.2680.9 ± 21.50
CF: Change at C2 D1 (n=234, 234)-1.1 ± 19.86-0.3 ± 17.74
CF: Change at C3 D1 (n=172, 179)-2.1 ± 20.43-0.9 ± 18.67
CF: Change at C4 D1 (n=134, 134)-4.2 ± 19.982.0 ± 18.62
CF: Change at C5 D1 (n=97, 80)-1.4 ± 20.211.7 ± 18.86
CF: Change at C6 D1 (n=60, 56)-3.1 ± 19.27-4.5 ± 19.97
CF: Change at C7 D1 (n=38, 34)-4.4 ± 18.450.5 ± 14.50
CF: Change at C8 D1 (n=17, 17)-8.8 ± 22.15-2.9 ± 23.74
CF: Change at C9 D1 (n=9, 9)-0.0 ± 25.03-1.8 ± 24.22
CF: Change at C10 D1 (n=3, 4)-5.6 ± 9.648.3 ± 28.88
CF: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
CF: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
CF: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
CF: Change at follow-up (n=65, 71)-12.6 ± 25.01-7.5 ± 25.47
Social functioning: Baseline (n=289, 286)68.9 ± 27.9869.7 ± 28.83
Social functioning: Change at C2 D1 (n=232, 230)1.3 ± 24.730.9 ± 26.35
Social functioning: Change at C3 D1 (n=169, 178)-1.3 ± 29.383.2 ± 27.31
Social functioning: Change at C4 D1 (n=132, 134)0.1 ± 25.510.6 ± 26.83
Social functioning: Change at C5 D1 (n=95, 80)2.1 ± 27.310.8 ± 27.93
Social functioning: Change at C6 D1 (n=58, 56)-4.9 ± 28.791.5 ± 29.52
Social functioning: Change at C7 D1 (n=37, 35)-5.4 ± 20.052.4 ± 29.47
Social functioning: Change at C8 D1 (n=17, 19)4.9 ± 29.91-1.7 ± 27.72
Social functioning: Change at C9 D1 (n=9, 9)-0.0 ± 32.29-1.8 ± 28.20
Social functioning: Change at C10 D1 (n=3, 4)5.6 ± 9.6412.5 ± 43.83
Social functioning: Change at C11 D1 (n=1, 1)0.0 ± NA33.4 ± NA
Social functioning: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Social functioning: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Social functioning: Change at follow-up (n=64, 70)-13.3 ± 33.75-2.6 ± 33.88
Fatigue: Baseline (n=293, 289)41.0 ± 23.8740.1 ± 25.12
Fatigue: Change at C2 D1 (n=227, 228)2.8 ± 21.152.1 ± 20.12
Fatigue: Change at C3 D1 (n=170, 181)3.4 ± 21.94-0.9 ± 21.76
Fatigue: Change at C4 D1 (n=132, 132)5.6 ± 23.97-1.1 ± 22.77
Fatigue: Change at C5 D1 (n=97, 80)-0.0 ± 24.391.1 ± 21.92
Fatigue: Change at C6 D1 (n=60, 57)5.0 ± 21.310.0 ± 21.22
Fatigue: Change at C7 D1 (n=38, 36)1.8 ± 20.612.2 ± 19.12
Fatigue: Change at C8 D1 (n=17, 20)7.2 ± 22.894.4 ± 22.05
Fatigue: Change at C9 D1 (n=9, 9)-6.2 ± 21.6314.8 ± 24.21
Fatigue: Change at C10 D1 (n=3, 4)-11.1 ± 19.28-5.5 ± 27.98
Fatigue: Change at C11 D1 (n=1, 1)0.0 ± NA11.1 ± NA
Fatigue: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Fatigue: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Fatigue: Change at follow-up (n=63, 71)13.1 ± 25.9312.1 ± 25.95
Nausea and vomiting: Baseline (n=295, 294)12.9 ± 19.1913.1 ± 19.75
Nausea and vomiting: Change at C2 D1 (n=238, 239)3.7 ± 20.692.9 ± 22.93
Nausea and vomiting: Change at C3 D1 (n=176, 185)1.9 ± 20.38-0.4 ± 19.54
Nausea and vomiting: Change at C4 D1 (n=133, 135)3.5 ± 20.820.4 ± 19.68
Nausea and vomiting: Change at C5 D1 (n=98, 81)4.6 ± 22.161.0 ± 18.88
Nausea and vomiting: Change at C6 D1 (n=60, 59)6.9 ± 22.612.8 ± 20.33
Nausea and vomiting: Change at C7 D1 (n=38, 37)1.3 ± 19.522.7 ± 20.24
Nausea and vomiting: Change at C8 D1 (n=17, 21)-4.9 ± 18.410.8 ± 22.66
Nausea and vomiting: Change at C9 D1 (n=9, 9)-13.0 ± 32.02-5.6 ± 18.64
Nausea and vomiting: Change at C10 D1 (n=3, 4)-11.1 ± 19.238.3 ± 9.58
Nausea and vomiting: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Nausea and vomiting: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Nausea and vomiting: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Nausea and vomiting: Change at followup (n=68, 73)9.8 ± 25.637.5 ± 22.40
Pain: Baseline (n=291, 291)40.7 ± 30.1636.9 ± 29.57
Pain: Change at C2 D1 (n=231, 234)-10.1 ± 29.47-7.9 ± 25.28
Pain: Change at C3 D1 (n=169, 181)-13.6 ± 29.81-11.2 ± 26.63
Pain: Change at C4 D1 (n=131, 135)-12.2 ± 32.48-7.8 ± 27.14
Pain: Change at C5 D1 (n=97, 80)-10.5 ± 32.75-6.9 ± 26.21
Pain: Change at C6 D1 (n=59, 58)-11.9 ± 27.51-7.5 ± 29.48
Pain: Change at C7 D1 (n=38, 35)-14.0 ± 27.81-9.5 ± 24.67
Pain: Change at C8 D1 (n=17, 20)-9.8 ± 26.39-6.7 ± 29.32
Pain: Change at C9 D1 (n=9, 9)-22.2 ± 43.29-5.6 ± 39.08
Pain: Change at C10 D1 (n=3, 4)-33.3 ± 33.30-4.2 ± 45.88
Pain: Change at C11 D1 (n=1, 1)0.0 ± NA-33.3 ± NA
Pain: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Pain: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Pain: Change at follow-up (n=66, 72)3.3 ± 37.013.5 ± 31.14
Dyspnoea: Baseline (n=295, 295)16.1 ± 22.3014.8 ± 23.55
Dyspnoea: Change at C2 D1 (n=238, 240)5.5 ± 23.582.1 ± 20.91
Dyspnoea: Change at C3 D1 (n=175, 186)5.7 ± 26.843.9 ± 24.67
Dyspnoea: Change at C4 D1 (n=135, 135)7.7 ± 26.994.4 ± 21.08
Dyspnoea: Change at C5 D1 (n=98, 82)4.4 ± 26.052.8 ± 18.29
Dyspnoea: Change at C6 D1 (n=60, 59)9.4 ± 26.09-0.0 ± 16.37
Dyspnoea: Change at C7 D1 (n=37, 37)6.3 ± 24.635.4 ± 20.05
Dyspnoea: Change at C8 D1 (n=16, 21)4.2 ± 20.6212.7 ± 24.66
Dyspnoea: Change at C9 D1 (n=9, 9)11.1 ± 47.1414.8 ± 29.39
Dyspnoea: Change at C10 D1 (n=3, 4)-11.1 ± 50.920.0 ± 27.19
Dyspnoea: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Dyspnoea: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Dyspnoea: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Dyspnoea: Change at follow-up (n=68, 73)13.2 ± 28.308.7 ± 24.23
Insomnia: Baseline (n=297, 295)36.8 ± 31.9532.2 ± 32.17
Insomnia: Change at C2 D1 (n=240, 241)-13.6 ± 33.55-7.3 ± 33.16
Insomnia: Change at C3 D1 (n=178, 185)-13.5 ± 33.33-8.7 ± 33.30
Insomnia: Change at C4 D1 (n=134, 134)-12.7 ± 38.52-11.2 ± 27.41
Insomnia: Change at C5 D1 (n=99, 82)-14.5 ± 33.05-7.3 ± 28.70
Insomnia: Change at C6 D1 (n=60, 59)-8.3 ± 30.46-2.3 ± 30.86
Insomnia: Change at C7 D1 (n=37, 37)-11.7 ± 36.19-2.7 ± 19.84
Insomnia: Change at C8 D1 (n=17, 21)5.9 ± 35.82-3.2 ± 20.82
Insomnia: Change at C9 D1 (n=9, 9)-14.8 ± 24.23-0.0 ± 23.56
Insomnia: Change at C10 D1 (n=3, 4)11.1 ± 19.23-0.0 ± 27.23
Insomnia: Change at C11 D1 (n=1, 1)0.0 ± NA33.3 ± NA
Insomnia: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Insomnia: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Insomnia: Change at follow-up (n=68, 73)1.5 ± 36.631.4 ± 28.02
Loss of appetite: Baseline (n=297, 295)39.6 ± 35.4937.5 ± 33.36
Loss of appetite: Change at C2 D1 (n=240, 240)-2.1 ± 34.24-2.6 ± 27.91
Loss of appetite: Change at C3 D1 (n=178, 186)-1.3 ± 31.57-5.9 ± 31.50
Loss of appetite: Change at C4 D1 (n=135, 135)0.0 ± 35.27-6.7 ± 29.88
Loss of appetite: Change at C5 D1 (n=99, 82)1.7 ± 35.76-4.5 ± 30.44
Loss of appetite: Change at C6 D1 (n=60, 59)2.8 ± 33.22-4.5 ± 29.34
Loss of appetite: Change at C7 D1 (n=38, 37)0.9 ± 35.92-7.2 ± 27.37
Loss of appetite: Change at C8 D1 (n=17, 20)7.8 ± 25.07-1.7 ± 29.57
Loss of appetite: Change at C9 D1 (n=9, 9)-14.8 ± 29.41-7.4 ± 36.44
Loss of appetite: Change at C10 D1 (n=3, 4)-22.2 ± 19.230.0 ± 38.48
Loss of appetite: Change at C11 D1 (n=1, 1)0.0 ± NA33.3 ± NA
Loss of appetite: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Loss of appetite: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Loss of appetite: Change at follow-up (n=67, 73)7.0 ± 39.177.8 ± 36.24
Constipation: Baseline (n=293, 289)30.7 ± 32.1329.6 ± 32.66
Constipation: Change at C2 D1 (n=234, 235)-4.8 ± 32.18-2.8 ± 33.21
Constipation: Change at C3 D1 (n =173, 181)-7.3 ± 32.12-6.1 ± 36.43
Constipation: Change at C4 D1 (n=134, 135)-6.5 ± 35.99-10.6 ± 36.80
Constipation: Change at C5 D1 (n=97, 80)-11.0 ± 33.59-8.7 ± 29.88
Constipation: Change at C6 D1 (n=60, 58)-5.6 ± 37.42-9.8 ± 32.45
Constipation: Change at C7 D1 (n=38, 36)-2.6 ± 31.37-13.0 ± 32.15
Constipation: Change at C8 D1 (n=17, 20)0.0 ± 28.87-16.7 ± 39.74
Constipation: Change at C9 D1 (n=9, 9)-18.5 ± 33.79-29.6 ± 35.14
Constipation: Change at C10 D1 (n=3, 4)-11.1 ± 19.23-50.0 ± 43.04
Constipation: Change at C11 D1 (n=1, 1)0.0 ± NA-66.7 ± NA
Constipation: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Constipation: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Constipation: Change at follow-up (n=66, 71)5.1 ± 42.27-6.1 ± 35.77
Diarrhoea: Baseline (n=294, 290)14.3 ± 21.6813.7 ± 24.19
Diarrhoea: Change at C2 D1 (n=235, 235)1.7 ± 25.730.3 ± 21.78
Diarrhoea: Change at C3 D1 (n=173, 182)9.4 ± 28.660.2 ± 23.10
Diarrhoea: Change at C4 D1 (n=134, 136)7.7 ± 28.00-1.5 ± 22.53
Diarrhoea: Change at C5 D1 (n=96, 81)11.8 ± 27.351.2 ± 27.10
Diarrhoea: Change at C6 D1 (n=60, 58)20.0 ± 33.721.7 ± 28.22
Diarrhoea: Change at C7 D1 (n=38, 36)14.9 ± 32.602.8 ± 23.05
Diarrhoea: Change at C8 D1 (n=17, 20)25.5 ± 38.241.7 ± 27.52
Diarrhoea: Change at C9 D1 (n=9, 9)37.0 ± 45.4722.2 ± 33.35
Diarrhoea: Change at C10 D1 (n=3, 4)22.2 ± 50.9116.7 ± 19.23
Diarrhoea: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Diarrhoea: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Diarrhoea: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Diarrhoea: Change at follow-up (n=66, 71)2.5 ± 29.412.8 ± 25.03
Financial difficulties (FD): Baseline (n=292, 285)24.7 ± 30.4123.0 ± 30.83
FD:Change at C2 D1 (n=233, 228)-3.1 ± 22.95-4.5 ± 23.29
FD: Change at C3 D1 (n=171, 176)-7.2 ± 26.94-3.4 ± 23.39
FD: Change at C4 D1 (n=133, 133)-5.5 ± 26.33-3.3 ± 23.52
FD: Change at C5 D1 (n=96, 80)-4.9 ± 21.621.3 ± 25.68
FD: Change at C6 D1 (n=60, 56)-3.9 ± 24.61-1.8 ± 28.02
FD: Change at C7 D1 (n=37, 34)-2.7 ± 24.06-3.9 ± 32.60
FD: Change at C8 D1 (n=17, 17)2.0 ± 14.282.0 ± 34.31
FD: Change at C9 D1 (n=9, 9)7.4 ± 22.233.7 ± 45.49
FD: Change at C10 D1 (n=3, 4)0.0 ± 0.0025.0 ± 41.94
FD: Change at C11 D1 (n=1, 1)0.0 ± NA66.7 ± NA
FD: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
FD: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
FD: Change at follow-up (n=65, 70)6.7 ± 29.59-0.5 ± 21.61
GHS/Quality of Life (QoL): Baseline (n=292, 288)54.2 ± 22.3457.1 ± 23.14
GHS/QoL:Change at C2 D1 (n=234, 233)2.2 ± 23.361.9 ± 22.39
GHS/QoL:Change at C3 D1 (n=168, 180)-0.3 ± 25.425.7 ± 21.45
GHS/QoL:Change at C4 D1(n=132, 132)0.1 ± 23.792.8 ± 21.54
GHS/QoL:Change at C5 D1 (n=96, 81)1.5 ± 22.632.7 ± 18.35
GHS/QoL:Change at C6 D1 (n=60, 57)0.8 ± 21.413.2 ± 23.40
GHS/QoL:Change at C7 D1 (n=38, 35)2.6 ± 23.012.1 ± 22.35
GHS/QoL:Change at C8 D1 (n=17, 19)-1.0 ± 23.731.3 ± 23.76
GHS/QoL:Change at C9 D1 (n=9, 9)7.4 ± 16.89-8.3 ± 20.39
GHS/QoL: Change at C10 D1 (n=3, 4)22.3 ± 19.28-0.0 ± 32.59
GHS/QoL: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
GHS/QoL: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
GHS/QoL: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
GHS/QoL:Change at follow-up (n=65, 71)-9.1 ± 26.06-6.7 ± 24.50
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score

QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.

Time frame:
Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score
Units on a scaleAxitinib + GemcitabinePlacebo + Gemcitabine
Pancreatic Pain: Baseline (n=246, 250)41.6 ± 27.1640.0 ± 25.54
Pancreatic Pain: Change at C2 D1 (n=191, 197)-10.9 ± 24.38-10.1 ± 22.93
Pancreatic Pain: Change at C3 D1 (n=141, 153)-16.3 ± 25.51-11.2 ± 24.92
Pancreatic Pain: Change at C4 D1 (n=99, 111)-13.2 ± 28.70-11.4 ± 26.16
Pancreatic Pain: Change at C5 D1 (n=67, 64)-15.8 ± 28.06-13.0 ± 23.85
Pancreatic Pain: Change at C6 D1 (n=41, 43)-15.9 ± 25.47-13.0 ± 24.62
Pancreatic Pain: Change at C7 D1 (n=25, 25)-15.3 ± 28.02-15.0 ± 25.69
Pancreatic Pain: Change at C8 D1 (n=11, 11)-7.6 ± 27.76-9.8 ± 30.01
Pancreatic Pain: Change at C9 D1 (n=6, 6)-29.2 ± 31.060.0 ± 15.81
Pancreatic Pain: Change at C10 D1 (n=2, 3)-20.9 ± 29.495.6 ± 26.79
Pancreatic Pain: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Pancreatic Pain: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Pancreatic Pain: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Pancreatic Pain: Change at follow-up (n=47, 46)-3.5 ± 29.59-3.6 ± 28.80
Hepatic: Baseline (n=245, 254)10.2 ± 17.2110.8 ± 17.59
Hepatic: Change at C2 D1 (n=193, 205)0.3 ± 18.24-2.0 ± 17.67
Hepatic: Change at C3 D1 (n=142, 157)-1.4 ± 16.78-2.5 ± 18.60
Hepatic: Change at C4 D1 (n=99, 112)-2.5 ± 18.34-2.4 ± 18.15
Hepatic: Change at C5 D1 (n=68, 64)1.0 ± 17.49-2.6 ± 16.60
Hepatic: Change at C6 D1 (n=40, 41)0.4 ± 15.34-3.2 ± 17.57
Hepatic: Change at C7 D1 (n=25, 24)-0.7 ± 16.30-4.9 ± 18.70
Hepatic: Change at C8 D1 (n=11, 12)-4.5 ± 13.10-4.2 ± 12.57
Hepatic: Change at C9 D1 (n=6, 5)-11.1 ± 13.60-13.3 ± 13.94
Hepatic: Change at C10 D1 (n=2, 2)-16.7 ± 23.55-8.4 ± 11.81
Hepatic: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Hepatic: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Hepatic: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Hepatic: Change at follow-up (n=47, 48)2.8 ± 23.38-1.4 ± 23.27
Digestive Symptom: Baseline (n=250, 255)34.3 ± 30.7833.9 ± 31.05
Digestive Symptom: Change at C2 D1 (n=195, 206)2.8 ± 29.150.6 ± 26.72
Digestive Symptom: Change at C3 D1 (n=144, 159)-1.2 ± 31.58-4.3 ± 32.97
Digestive Symptom: Change at C4 D1 (n=100, 114)0.5 ± 30.57-4.5 ± 30.90
Digestive Symptom: Change at C5 D1 (n=69, 65)1.4 ± 32.80-3.6 ± 36.14
Digestive Symptom: Change at C6 D1 (n=40, 45)3.3 ± 30.230.4 ± 35.97
Digestive Symptom: Change at C7 D1 (n=25, 26)-6.0 ± 30.76-1.3 ± 24.91
Digestive Symptom: Change at C8 D1 (n=11, 14)4.5 ± 42.8717.9 ± 23.07
Digestive Symptom: Change at C9 D1 (n=6, 6)-13.9 ± 46.4422.2 ± 25.10
Digestive Symptom: Change at C10 D1 (n=2, 3)-33.3 ± 47.0911.1 ± 19.23
Digestive Symptom: Change at C11 D1 (n=1, 1)0.0 ± NA66.7 ± NA
Digestive Symptom: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Digestive Symptom: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Digestive Symptom: Change at follow-up (n=47, 47)6.0 ± 38.142.8 ± 35.83
Sexuality: Baseline (n=217, 232)56.8 ± 36.9055.5 ± 38.04
Sexuality: Change at C2 D1 (n=157, 181)-0.5 ± 37.81-4.0 ± 33.17
Sexuality: Change at C3 D1 (n=118, 139)-4.9 ± 37.70-3.0 ± 32.25
Sexuality: Change at C4 D1 (n=85, 100)-4.1 ± 38.403.0 ± 29.90
Sexuality: Change at C5 D1 (n=55, 58)-1.5 ± 34.30-5.2 ± 29.32
Sexuality: Change at C6 D1 (n=30, 38)12.2 ± 29.67-11.4 ± 33.58
Sexuality: Change at C7 D1 (n=19, 21)4.4 ± 35.06-7.1 ± 31.88
Sexuality: Change at C8 D1 (n=8, 10)12.5 ± 24.82-15.0 ± 26.59
Sexuality: Change at C9 D1 (n=4, 6)25.0 ± 31.930.0 ± 23.55
Sexuality: Change at C10 D1 (n=0, 3)NA ± NA11.1 ± 19.28
Sexuality: Change at C11 D1 (n=0, 1)NA ± NA33.3 ± NA
Sexuality: Change at C12 D1 (n=0, 0)NA ± NANA ± NA
Sexuality: Change at C13 D1 (n=0, 0)NA ± NANA ± NA
Sexuality: Change at follow-up (n=36, 41)-3.2 ± 41.18-23.2 ± 42.31
Health care(HC)satisfaction: Baseline (n=241, 247)78.0 ± 26.6678.3 ± 23.94
HC satisfaction: Change at C2 D1 (n=182, 194)0.1 ± 27.731.8 ± 24.13
HC satisfaction: Change at C3 D1 (n=135, 149)0.2 ± 31.545.4 ± 24.98
HC satisfaction: Change at C4 D1 (n=97, 108)-4.3 ± 34.88-0.2 ± 26.52
HC satisfaction: Change at C5 D1 (n=66, 59)1.0 ± 29.660.8 ± 28.77
HC satisfaction: Change at C6 D1 (n=40, 39)-6.7 ± 26.91-0.4 ± 27.96
HC satisfaction: Change at C7 D1 (n=27, 20)-4.3 ± 22.446.7 ± 33.06
HC satisfaction: Change at C8 D1 (n=12, 11)-16.7 ± 52.237.6 ± 20.22
HC satisfaction: Change at C9 D1 (n=6, 6)16.7 ± 47.14-5.6 ± 17.23
HC satisfaction: Change at C10 D1 (n=2, 3)-33.3 ± 0.05.6 ± 9.64
HC satisfaction: Change at C11 D1 (n=1, 1)-33.3 ± NA0.0 ± NA
HC satisfaction: Change at C12 D1 (n=1, 0)-33.3 ± NANA ± NA
HC satisfaction: Change at C13 D1(n=1, 0)-33.3 ± NANA ± NA
HC satisfaction: Change at follow-up (n=46, 45)-0.7 ± 29.39-2.2 ± 31.50
Body Image: Baseline (n=249, 251)28.5 ± 28.4628.8 ± 28.67
Body Image: Change at C2 D1 (n=189, 200)4.9 ± 23.11-0.2 ± 26.78
Body Image: Change at C3 D1 (n=142, 149)4.9 ± 22.262.1 ± 26.16
Body Image: Change at C4 D1 (n=97, 111)6.7 ± 26.200.9 ± 26.48
Body Image: Change at C5 D1 (n=70, 62)4.8 ± 26.33-0.3 ± 25.87
Body Image: Change at C6 D1 (n=40, 42)8.3 ± 28.24-0.8 ± 33.92
Body Image: Change at C7 D1 (n=25, 24)12.0 ± 27.43-5.6 ± 33.22
Body Image: Change at C8 D1 (n=11, 12)21.2 ± 42.2311.1 ± 32.04
Body Image: Change at C9 D1 (n=6, 6)33.3 ± 52.698.3 ± 46.87
Body Image: Change at C10 D1 (n=2, 3)-8.3 ± 11.745.6 ± 78.77
Body Image: Change at C11 D1 (n=1, 1)0.0 ± NA-50.0 ± NA
Body Image: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Body Image: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Body Image: Change at follow-up (n=47, 45)13.1 ± 30.6711.5 ± 24.56
Altered Bowel Habit: Baseline (n=250, 255)20.3 ± 22.9221.2 ± 25.72
Altered Bowel Habit: Change at C2 D1 (n=193, 204)3.0 ± 24.191.5 ± 22.21
Altered Bowel Habit: Change at C3 D1 (n=143, 156)6.2 ± 26.372.5 ± 24.67
Altered Bowel Habit: Change at C4 D1 (n=98, 114)6.6 ± 25.524.8 ± 22.14
Altered Bowel Habit: Change at C5 D1 (n=68, 63)8.3 ± 33.151.3 ± 24.56
Altered Bowel Habit: Change at C6 D1 (n=40, 43)9.6 ± 30.632.3 ± 28.07
Altered Bowel Habit: Change at C7 D1 (n=25, 25)6.0 ± 25.401.3 ± 30.77
Altered Bowel Habit: Change at C8 D1 (n=11, 13)1.5 ± 29.297.7 ± 38.86
Altered Bowel Habit: Change at C9 D1 (n=6, 6)13.9 ± 32.35-5.6 ± 51.27
Altered Bowel Habit: Change at C10 D1 (n=2, 3)-8.3 ± 35.36-16.7 ± 72.62
Altered Bowel Habit: Change at C11 D1 (n=1, 1)16.7 ± NA-100.0 ± NA
Altered Bowel Habit: Change at C12 D1 (n=1, 0)16.7 ± NANA ± NA
Altered Bowel Habit: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Altered Bowel Habit: Change at followup (n=47, 48)6.0 ± 29.365.9 ± 21.33
Ascites: Baseline (n=250, 256)38.7 ± 32.9832.9 ± 30.61
Ascites: Change at C2 D1 (n=197, 207)-8.6 ± 33.32-3.4 ± 29.65
Ascites: Change at C3 D1 (n=144, 158)-8.3 ± 33.34-5.1 ± 28.70
Ascites: Change at C4 D1 (n=101, 114)-5.0 ± 36.64-0.3 ± 26.05
Ascites: Change at C5 D1 (n=71, 65)-8.5 ± 34.15-0.5 ± 29.17
Ascites: Change at C6 D1 (n=42, 45)-3.2 ± 31.08-2.2 ± 32.10
Ascites: Change at C7 D1 (n=26, 26)-14.1 ± 32.91-12.8 ± 23.25
Ascites: Change at C8 D1 (n=11, 14)-18.2 ± 43.12-11.9 ± 28.05
Ascites: Change at C9 D1 (n=6, 6)-11.1 ± 34.42-16.7 ± 34.95
Ascites: Change at C10 D1 (n=2, 3)-16.7 ± 23.5522.2 ± 38.51
Ascites: Change at C11 D1 (n=1, 1)0.0 ± NA33.3 ± NA
Ascites: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Ascites: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Ascites: Change at follow-up (n=48, 48)5.6 ± 35.96-2.1 ± 26.11
Indigestion: Baseline (n=252, 257)29.4 ± 30.3824.0 ± 28.55
Indigestion: Change at C2 D1 (n=198, 208)-0.3 ± 26.87-2.4 ± 24.29
Indigestion: Change at C3 D1 (n=144, 159)0.2 ± 30.16-5.2 ± 25.59
Indigestion: Change at C4 D1 (n=101, 115)-4.0 ± 24.63-4.1 ± 25.80
Indigestion: Change at C5 D1 (n=71, 65)0.5 ± 29.01-4.6 ± 22.72
Indigestion: Change at C6 D1 (n=41, 45)1.6 ± 31.58-1.5 ± 24.57
Indigestion: Change at C7 D1 (n=26, 26)-3.8 ± 19.60-1.3 ± 17.59
Indigestion: Change at C8 D1 (n=11, 14)0.0 ± 21.062.4 ± 20.53
Indigestion: Change at C9 D1 (n=6, 6)-5.6 ± 25.0711.1 ± 27.23
Indigestion: Change at C10 D1 (n=2, 3)-16.7 ± 23.5522.2 ± 19.23
Indigestion: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Indigestion: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Indigestion: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Indigestion: Change at follow-up (n=48, 48)7.6 ± 30.941.4 ± 30.73
Flatulence: Baseline (n=249, 256)37.9 ± 32.3434.0 ± 31.31
Flatulence: Change at C2 D1 (n=197, 206)1.2 ± 29.812.6 ± 31.82
Flatulence: Change at C3 D1 (n=146, 159)3.2 ± 33.070.2 ± 34.48
Flatulence: Change at C4 D1 (n=101, 115)-1.3 ± 33.652.3 ± 32.07
Flatulence: Change at C5 D1 (n=70, 65)-1.0 ± 32.601.0 ± 31.17
Flatulence: Change at C6 D1 (n=41, 45)-1.6 ± 26.83-1.5 ± 29.27
Flatulence: Change at C7 D1 (n=25, 26)-1.3 ± 26.31-3.8 ± 23.71
Flatulence: Change at C8 D1 (n=10, 14)-10.0 ± 35.342.4 ± 27.62
Flatulence: Change at C9 D1 (n=5, 6)0.0 ± 0.005.6 ± 13.59
Flatulence: Change at C10 D1 (n=1, 3)33.3 ± NA-11.1 ± 19.23
Flatulence: Change at C11 D1 (n=0, 1)NA ± NA0.0 ± NA
Flatulence: Change at C12 D1 (n=0, 0)NA ± NANA ± NA
Flatulence: Change at C13 D1 (n=0, 0)NA ± NANA ± NA
Flatulence: Change at follow-up (n=48, 46)-0.7 ± 35.412.2 ± 34.00
Cachexia: Baseline (n=251, 253)33.1 ± 27.6233.6 ± 26.84
Cachexia: Change at C2 D1 (n=197, 205)4.2 ± 24.260.6 ± 21.63
Cachexia: Change at C3 D1 (n=145, 157)4.6 ± 25.87-3.3 ± 21.13
Cachexia: Change at C4 D1 (n=101, 112)1.2 ± 26.37-6.2 ± 24.82
Cachexia: Change at C5 D1 (n=70, 64)0.5 ± 28.37-8.3 ± 24.48
Cachexia: Change at C6 D1 (n=40, 44)-2.1 ± 24.80-5.3 ± 24.84
Cachexia: Change at C7 D1 (n=24, 26)-0.7 ± 24.31-5.1 ± 25.27
Cachexia: Change at C8 D1 (n=10, 14)15.0 ± 34.64-4.7 ± 21.12
Cachexia: Change at C9 D1 (n=5, 6)16.7 ± 31.162.8 ± 19.47
Cachexia: Change at C10 D1 (n=1, 3)0.0 ± NA0.0 ± 28.87
Cachexia: Change at C11 D1 (n=0, 1)NA ± NA-16.6 ± NA
Cachexia: Change at C12 D1 (n=0, 0)NA ± NANA ± NA
Cachexia: Change at C13 D1 (n=0, 0)NA ± NANA ± NA
Cachexia: Change at follow-up (n=48, 47)8.0 ± 31.696.4 ± 30.79
Side Effects: Baseline (n=209, 226)24.9 ± 21.2127.4 ± 23.08
Side Effects: Change at C2 D1 (n=159, 181)11.2 ± 23.115.8 ± 22.06
Side Effects: Change at C3 D1 (n=113, 137)13.0 ± 24.674.7 ± 22.18
Side Effects: Change at C4 D1 (n=80, 102)10.1 ± 20.644.9 ± 22.48
Side Effects: Change at C5 D1 (n=54, 59)7.4 ± 25.553.6 ± 23.84
Side Effects: Change at C6 D1 (n=29, 40)8.1 ± 26.72-1.4 ± 25.32
Side Effects: Change at C7 D1 (n=17, 22)15.0 ± 20.77-1.0 ± 19.38
Side Effects: Change at C8 D1 (n=8, 11)9.7 ± 19.19-3.0 ± 22.83
Side Effects: Change at C9 D1 (n=3, 6)14.8 ± 23.15-1.9 ± 27.60
Side Effects: Change at C10 D1 (n=0, 3)NA ± NA0.0 ± 40.12
Side Effects: Change at C11 D1 (n=0, 1)NA ± NA-33.4 ± NA
Side Effects: Change at C12 D1 (n=0, 0)NA ± NANA ± NA
Side Effects: Change at C13 D1 (n=0, 0)NA ± NANA ± NA
Side Effects: Change at follow-up (n=42, 42)18.8 ± 24.3713.2 ± 27.80
Fear of Future Health (FH): Baseline (n=252, 250))59.3 ± 31.3361.1 ± 33.07
Fear of FH: Change at C2 D1 (n=192, 201)-3.5 ± 31.82-9.6 ± 28.80
Fear of FH: Change at C3 D1 (n=145, 155)-0.9 ± 34.02-11.6 ± 30.07
Fear of FH: Change at C4 D1 (n=103, 113)-4.5 ± 32.70-15.9 ± 30.90
Fear of FH: Change at C5 D1 (n=71, 64)-0.5 ± 31.12-10.9 ± 29.74
Fear of FH: Change at C6 D1 (n=42, 44)-4.8 ± 30.86-14.4 ± 32.47
Fear of FH: Change at C7 D1 (n=27, 25)-6.2 ± 22.72-13.3 ± 33.34
Fear of FH: Change at C8 D1 (n=12, 12)2.8 ± 30.025.6 ± 27.84
Fear of FH: Change at C9 D1 (n=6, 6)16.7 ± 27.9016.7 ± 34.96
Fear of FH: Change at C10 D1 (n=2, 3)-16.7 ± 23.6211.1 ± 50.96
Fear of FH: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Fear of FH: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Fear of FH: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Fear of FH:Change at follow-up (n=48, 45)5.6 ± 28.63-4.4 ± 38.67
Future Plan ability: Baseline (n=250, 249)34.3 ± 33.5938.0 ± 34.40
Future Plan ability: Change at C2 D1 (n=192, 198)6.1 ± 38.19-0.3 ± 34.58
Future Plan ability:Change at C3 D1 (n=142, 153)3.5 ± 39.650.4 ± 36.68
Future Plan ability:Change at C4 D1 (n=101, 112)5.6 ± 36.550.3 ± 37.04
Future Plan ability:Change at C5 D1 (n=70, 62)0.9 ± 34.05-3.8 ± 39.17
Future Plan ability:Change at C6 D1 (n=42, 42)4.8 ± 34.990.8 ± 46.27
Future Plan ability: Change at C7 D1 (n=26, 24)2.6 ± 28.18-7.0 ± 36.76
Future Plan ability: Change at C8 D1 (n=11, 11)6.1 ± 32.743.0 ± 43.36
Future Plan ability: Change at C9 D1 (n=5, 6)0.0 ± 23.550.0 ± 55.78
Future Plan ability: Change at C10 D1 (n=1, 3)0.0 ± NA-11.1 ± 69.43
Future Plan ability: Change at C11 D1 (n=1, 1)0.0 ± NA-66.7 ± NA
Future Plan ability: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Future Plan ability: Change at C13 D1 (n=1, 0)0.0 ± NANA ± NA
Future Plan ability: Change at followup (n=48, 45)21.5 ± 35.405.2 ± 38.25
SecondaryChange From Baseline Brief Pain Inventory-short Form (BPI-sf) Score

BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.

Time frame:
Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Reported as:
Mean · Units on a scale
Change From Baseline Brief Pain Inventory-short Form (BPI-sf) Score
Units on a scaleAxitinib + GemcitabinePlacebo + Gemcitabine
Worst Pain: Baseline (n=247, 250)3.8 ± 2.843.7 ± 2.96
Worst Pain: Change at C2 D1 (n=192, 200)-0.7 ± 3.04-0.9 ± 2.84
Worst Pain: Change at C3 D1 (n=138, 151)-1.5 ± 3.09-0.9 ± 2.83
Worst Pain: Change at C4 D1 (n=99, 113)-1.0 ± 3.41-0.9 ± 3.09
Worst Pain: Change at C5 D1 (n=69, 64)-1.1 ± 3.43-1.2 ± 3.08
Worst Pain: Change at C6 D1 (n=41, 43)-0.9 ± 2.98-1.0 ± 3.17
Worst Pain: Change at C7 D1 (n=25, 26)-0.8 ± 2.27-0.9 ± 3.50
Worst Pain: Change at C8 D1 (n=12, 13)0.8 ± 2.56-1.5 ± 3.20
Worst Pain: Change at C9 D1(n=6, 6)-1.8 ± 1.94-1.3 ± 1.51
Worst Pain: Change at C10 D1 (n=2, 3)-2.0 ± 2.83-0.3 ± 2.31
Worst Pain: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Worst Pain: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Worst Pain: Change at C13 D1 (n=1, 1)0.0 ± NA-4.0 ± NA
Worst Pain: Change at follow-up (n=47, 46)0.5 ± 3.080.0 ± 3.21
Pain in Last 24 Hours (hrs): Baseline (n=246, 248)1.8 ± 1.921.7 ± 1.93
Pain in Last 24 hrs: Change at C2 D1 (n=193, 197)-0.2 ± 2.21-0.3 ± 1.92
Pain in Last 24 hrs: Change at C3 D1 (n=138, 150)-0.6 ± 2.01-0.3 ± 1.88
Pain in Last 24 hrs: Change at C4 D1 (n=99, 112)-0.3 ± 2.15-0.0 ± 1.96
Pain in Last 24 hrs: Change at C5 D1 (n=69, 63)-0.3 ± 2.41-0.2 ± 2.04
Pain in Last 24 hrs: Change at C6 D1 (n=40, 43)-0.2 ± 2.07-0.1 ± 1.64
Pain in Last 24 hrs: Change at C7 D1 (n=25, 26)0.4 ± 1.47-0.0 ± 2.46
Pain in Last 24 hrs: Change at C8 D1 (n=12, 13)1.3 ± 2.34-0.2 ± 1.41
Pain in Last 24 hrs: Change at C9 D1 (n=6, 6)-0.3 ± 1.370.2 ± 1.60
Pain in Last 24 hrs: Change at C10 D1 (n=2, 3)-1.5 ± 2.120.3 ± 0.58
Pain in Last 24 hrs: Change at C11 D1 (n=1, 1)0.0 ± NA4.0 ± NA
Pain in Last 24 hrs: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Pain in Last 24 hrs: Change at C13 D1 (n=1, 1)0.0 ± NA-1.0 ± NA
Pain in Last 24 hrs: Change at followup (n=48, 45)0.4 ± 2.700.8 ± 2.58
Pain on the Average: Baseline (n=246, 248)2.9 ± 2.162.8 ± 2.27
Pain on the Average: Change at C2 D1 (n=195, 198)-0.5 ± 2.02-0.5 ± 2.29
Pain on the Average: Change at C3 D1 (n=140, 149)-0.8 ± 2.48-0.5 ± 2.10
Pain on the Average: Change at C4 D1 (n=99, 113)-0.7 ± 2.44-0.6 ± 2.03
Pain on the Average: Change at C5 D1 (n=69, 63)-0.7 ± 2.48-0.6 ± 2.29
Pain on the Average: Change at C6 D1 (n=40, 43)-0.5 ± 2.07-0.9 ± 2.12
Pain on the Average: Change at C7 D1 (n=25, 26)-0.3 ± 1.46-0.5 ± 2.97
Pain on the Average: Change at C8 D1 (n=12, 13)1.0 ± 2.00-1.4 ± 1.94
Pain on the Average: Change at C9 D1 (n=6, 6)-1.7 ± 1.51-1.7 ± 1.86
Pain on the Average: Change at C10 D1 (n=2, 3)-2.0 ± 2.83-1.0 ± 2.65
Pain on the Average: Change at C11 D1 (n=1, 1)0.0 ± NA-3.0 ± NA
Pain on the Average: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Pain on the Average: Change at C13 D1 (n=1, 1)0.0 ± NA-2.0 ± NA
Pain on the Average: Change at followup (n=48, 45)0.6 ± 2.700.4 ± 2.74
Pain Right Now: Baseline (n=248, 249)2.1 ± 2.132.1 ± 2.36
Pain Right Now: Change at C2 D1 (n=196, 200)-0.4 ± 2.23-0.5 ± 2.37
Pain Right Now: Change at C3 D1 (n=140, 150)-0.8 ± 2.31-0.6 ± 2.06
Pain Right Now: Change at C4 D1 (n=99, 113)-0.6 ± 2.26-0.5 ± 2.45
Pain Right Now: Change at C5 D1 (n=68, 63)-0.5 ± 2.76-0.3 ± 2.65
Pain Right Now: Change at C6 D1 (n=40, 43)-0.5 ± 1.96-0.5 ± 2.14
Pain Right Now: Change at C7 D1 (n=25, 26)0.1 ± 1.66-0.2 ± 3.26
Pain Right Now: Change at C8 D1 (n=12, 13)1.1 ± 1.93-0.6 ± 1.56
Pain Right Now: Change at C9 D1 (n=6, 6)-1.5 ± 1.76-0.3 ± 0.52
Pain Right Now: Change at C10 D1 (n=2, 3)-2.0 ± 2.830.7 ± 1.15
Pain Right Now: Change at C11 D1 (n=1, 1)0.0 ± NA5.0 ± NA
Pain Right Now: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Pain Right Now: Change at C13 D1 (n=1, 1)0.0 ± NA-5.0 ± NA
Pain Right Now: Change at follow-up (n=48, 46)0.4 ± 2.64-0.0 ± 2.67
Relief Pain Treatment (Tx): Baseline (n=226, 221)7.8 ± 12.096.9 ± 9.71
Relief Pain Tx: Change at C2 D1 (n=164, 165)0.6 ± 13.960.4 ± 11.48
Relief Pain Tx: Change at C3 D1 (n=122, 124)-2.1 ± 13.100.1 ± 9.16
Relief Pain Tx: Change at C4 D1 (n=88, 92)-1.7 ± 13.51-0.9 ± 17.56
Relief Pain Tx: Change at C5 D1 (n=59, 51)-2.9 ± 16.351.8 ± 11.62
Relief Pain Tx: Change at C6 D1 (n=34, 33)-1.6 ± 11.900.5 ± 4.28
Relief Pain Tx: Change at C7 D1 (n=21, 18)1.0 ± 2.78-3.2 ± 19.65
Relief Pain Tx: Change at C8 D1 (n=10, 8)-5.0 ± 21.20-11.6 ± 28.16
Relief Pain Tx: Change at C9 D1 (n=5, 5)-14.0 ± 28.99-16.6 ± 35.44
Relief Pain Tx: Change at C10 D1 (n=1, 2)6.0 ± NA0.0 ± 1.41
Relief Pain Tx: Change at C11 D1 (n=0, 1)NA ± NA0.0 ± NA
Relief Pain Tx: Change at C12 D1 (n=0, 0)NA ± NANA ± NA
Relief Pain Tx: Change at C13 D1 (n=0, 0)NA ± NANA ± NA
Relief Pain Tx: Change at follow-up (n=43, 36)0.2 ± 3.82-0.4 ± 5.08
General Activity: Baseline (n=243, 243)3.2 ± 3.113.0 ± 3.01
General Activity: Change at C2 D1 (n=190, 193)-0.6 ± 2.96-0.7 ± 2.55
General Activity: Change at C3 D1 (n=135, 143)-1.1 ± 3.47-0.7 ± 2.61
General Activity: Change at C4 D1 (n=97, 109)-0.4 ± 3.10-0.8 ± 2.53
General Activity: Change at C5 D1 (n=66, 62)-0.8 ± 3.64-0.5 ± 2.51
General Activity: Change at C6 D1 (n=40, 41)-0.6 ± 3.82-0.7 ± 2.62
General Activity: Change at C7 D1 (n=25, 25)-0.5 ± 2.87-0.4 ± 2.84
General Activity: Change at C8 D1 (n=12, 12)0.1 ± 2.07-0.8 ± 2.70
General Activity: Change at C9 D1 (n=6, 6)-2.2 ± 2.710.3 ± 3.72
General Activity: Change at C10 D1 (n=2, 3)-2.5 ± 3.543.0 ± 5.29
General Activity: Change at C11 D1 (n=1, 1)0.0 ± NA1.0 ± NA
General Activity: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
General Activity: Change at C13 D1 (n=1, 1)0.0 ± NA-1.0 ± NA
General Activity: Change at follow-up (n=47, 44)1.0 ± 4.320.0 ± 3.63
Mood: Baseline (n=243, 241)3.0 ± 2.922.8 ± 2.77
Mood: Change at C2 D1 (n=191, 191)-0.6 ± 2.74-0.2 ± 2.46
Mood: Change at C3 D1 (n=135, 141)-1.0 ± 3.39-0.5 ± 2.51
Mood: Change at C4 D1 (n=98, 106)-0.3 ± 3.22-0.9 ± 2.81
Mood: Change at C5 D1 (n=66, 61)-0.7 ± 3.66-0.9 ± 2.59
Mood: Change at C6 D1 (n=40, 41)-0.6 ± 3.23-0.8 ± 2.93
Mood: Change at C7 D1 (n=25, 25)0.0 ± 2.54-0.2 ± 3.18
Mood: Change at C8 D1 (n=12, 12)0.6 ± 1.31-1.1 ± 3.12
Mood: Change at C9 D1 (n=6, 6)-1.3 ± 1.97-0.8 ± 3.31
Mood: Change at C10 D1 (n=2, 3)-1.0 ± 1.413.3 ± 1.53
Mood: Change at C11 D1 (n=1, 1)0.0 ± NA5.0 ± NA
Mood: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Mood: Change at C13 D1 (n=1, 1)0.0 ± NA-3.0 ± NA
Mood: Change at follow-up (n=47, 44)0.9 ± 3.650.2 ± 3.62
Walking Ability: Baseline (n=242, 243)2.2 ± 2.782.3 ± 2.81
Walking Ability: Change at C2 D1 (n=189, 194)0.1 ± 2.84-0.1 ± 2.61
Walking Ability: Change at C3 D1 (n=133, 143)-0.2 ± 3.41-0.3 ± 2.52
Walking Ability: Change at C4 D1 (n=97, 108)0.3 ± 3.32-0.4 ± 2.64
Walking Ability: Change at C5 D1 (n=66, 62)0.1 ± 3.49-0.3 ± 2.37
Walking Ability: Change at C6 D1 (n=41, 41)0.5 ± 2.86-0.2 ± 2.24
Walking Ability: Change at C7 D1 (n=25, 25)1.1 ± 2.67-0.1 ± 2.42
Walking Ability: Change at C8 D1 (n=12, 12)0.7 ± 2.46-1.3 ± 2.42
Walking Ability: Change at C9 D1 (n=6, 6)-1.0 ± 3.520.2 ± 4.62
Walking Ability: Change at C10 D1 (n=2, 3)-2.0 ± 2.831.3 ± 5.51
Walking Ability: Change at C11 D1 (n=1, 1)0.0 ± NA0.0 ± NA
Walking Ability: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Walking Ability: Change at C13 D1 (n=1, 1)0.0 ± NA-2.0 ± NA
Walking Ability: Change at follow-up (n=47, 45)0.9 ± 4.130.7 ± 3.27
Normal Work: Baseline (n=240, 240)3.5 ± 3.343.2 ± 3.23
Normal Work: Change at C2 D1 (n=187, 191)-0.4 ± 3.24-0.1 ± 3.16
Normal Work: Change at C3 D1 (n=133, 139)-0.6 ± 3.33-0.4 ± 2.67
Normal Work: Change at C4 D1 (n=96, 107)-0.2 ± 3.15-0.7 ± 2.90
Normal Work: Change at C5 D1 (n=65, 61)-0.7 ± 3.86-0.6 ± 2.71
Normal Work: Change at C6 D1 (n=39, 41)0.2 ± 3.62-0.2 ± 3.12
Normal Work: Change at C7 D1 (n=25, 24)0.5 ± 2.76-0.4 ± 2.52
Normal Work: Change at C8 D1 (n=12, 12)-0.3 ± 3.70-0.1 ± 3.37
Normal Work: Change at C9 D1 (n=6, 6)-1.5 ± 3.513.5 ± 4.32
Normal Work: Change at C10 D1 (n=2, 3)-0.5 ± 0.711.3 ± 3.51
Normal Work: Change at C11 D1 (n=1, 1)0.0 ± NA2.0 ± NA
Normal Work: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Normal Work: Change at C13 D1 (n=1, 1)0.0 ± NA-2.0 ± NA
Normal Work: Change at follow-up (n=46, 43)1.0 ± 4.540.3 ± 3.90
Relations: Baseline (n=244, 242)2.3 ± 2.931.9 ± 2.44
Relations: Change at C2 D1 (n=190, 193)-0.3 ± 2.820.0 ± 2.18
Relations: Change at C3 D1 (n=136, 142)-0.4 ± 3.81-0.0 ± 2.16
Relations: Change at C4 D1 (n=98, 108)-0.2 ± 3.36-0.1 ± 2.52
Relations: Change at C5 D1 (n=66, 62)-0.6 ± 3.11-0.1 ± 2.27
Relations: Change at C6 D1 (n=40, 41)-0.3 ± 4.01-0.1 ± 2.76
Relations: Change at C7 D1 (n=25, 25)0.8 ± 3.32-0.7 ± 2.44
Relations: Change at C8 D1 (n=12, 12)0.6 ± 2.61-0.9 ± 2.35
Relations: Change at C9 D1 (n=6, 6)-1.2 ± 2.930.8 ± 4.88
Relations: Change at C10 D1 (n=2, 3)1.0 ± 1.412.7 ± 2.52
Relations: Change at C11 D1 (n=1, 1)0.0 ± NA2.0 ± NA
Relations: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Relations: Change at C13 D1 (n=1, 1)0.0 ± NA-2.0 ± NA
Relations: Change at follow-up (n=47, 45)0.7 ± 3.940.8 ± 3.56
Sleep: Baseline (n=244, 242)3.3 ± 3.163.2 ± 3.17
Sleep: Change at C2 D1 (n=191, 193)-1.1 ± 3.36-0.9 ± 2.73
Sleep: Change at C3 D1 (n=136, 142)-1.6 ± 3.52-1.1 ± 2.89
Sleep: Change at C4 D1 (n=98, 107)-1.2 ± 3.29-1.2 ± 3.02
Sleep: Change at C5 D1 (n=66, 62)-1.3 ± 4.06-0.8 ± 3.37
Sleep: Change at C6 D1(n=39, 41)-1.5 ± 3.22-0.8 ± 3.62
Sleep: Change at C7 D1 (n=25, 25)-0.2 ± 3.61-0.6 ± 2.81
Sleep: Change at C8 D1 (n=12, 12)0.6 ± 2.71-1.2 ± 3.51
Sleep: Change at C9 D1 (n=6, 6)-2.3 ± 3.200.3 ± 2.07
Sleep: Change at C10 D1 (n=2, 3)1.0 ± 1.410.7 ± 3.51
Sleep: Change at C11 D1 (n=1, 1)0.0 ± NA4.0 ± NA
Sleep: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Sleep: Change at C13 D1 (n=1, 1)0.0 ± NA-5.0 ± NA
Sleep: Change at follow-up (n=47, 44)0.5 ± 3.65-0.3 ± 3.54
Enjoyment of Life: Baseline (n=242, 240)3.5 ± 3.343.4 ± 3.17
Enjoyment of Life: Change at C2 D1 (n=191, 191)-0.6 ± 2.99-0.5 ± 2.89
Enjoyment of Life: Change at C3 D1 (n=134, 142)-0.7 ± 3.64-0.7 ± 2.77
Enjoyment of Life: Change at C4 D1 (n=98, 107)-0.6 ± 3.58-0.9 ± 2.70
Enjoyment of Life: Change at C5 D1 (n=66, 62)-0.6 ± 4.03-0.8 ± 3.07
Enjoyment of Life: Change at C6 D1 (n=40, 41)-0.4 ± 3.87-1.0 ± 3.17
Enjoyment of Life: Change at C7 D1 (n=25, 25)0.4 ± 3.53-0.9 ± 2.28
Enjoyment of Life: Change at C8 D1 (n=12, 12)0.8 ± 2.98-0.8 ± 2.53
Enjoyment of Life: Change at C9 D1 (n=6, 6)-0.5 ± 5.010.2 ± 2.86
Enjoyment of Life: Change at C10 D1 (n=2, 3)0.5 ± 0.712.3 ± 5.51
Enjoyment of Life: Change at C11 D1 (n=1, 1)0.0 ± NA-1.0 ± NA
Enjoyment of Life: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Enjoyment of Life: Change at C13 D1 (n=1, 1)0.0 ± NA-4.0 ± NA
Enjoyment of Life: Change at follow-up (n=47, 43)0.2 ± 3.68-0.2 ± 3.99
Combined Pain Intensity(PI): Baseline (n=248, 251)2.7 ± 1.982.6 ± 2.12
Combined PI: Change at C2 D1 (n=196, 202)-0.4 ± 1.97-0.5 ± 1.97
Combined PI: Change at C3 D1 (n=140, 151)-0.9 ± 2.15-0.6 ± 1.88
Combined PI: Change at C4 D1 (n=99, 114)-0.6 ± 2.19-0.5 ± 1.99
Combined PI: Change at C5 D1 (n=69, 64)-0.6 ± 2.46-0.6 ± 2.19
Combined PI: Change at C6 D1 (n=41, 43)-0.5 ± 1.92-0.6 ± 1.89
Combined PI: Change at C7 D1 (n=25, 27)-0.1 ± 1.48-0.4 ± 2.78
Combined PI: Change at C8 D1 (n=12, 13)1.0 ± 2.01-0.9 ± 1.76
Combined PI: Change at C9 D1 (n=6, 6)-1.3 ± 1.51-0.8 ± 1.11
Combined PI: Change at C10 D1 (n=2, 3)-1.9 ± 2.69-0.1 ± 1.44
Combined PI: Change at C11 D1 (n=1, 1)0.0 ± NA1.5 ± NA
Combined PI: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Combined PI: Change at C13 D1 (n=1, 1)0.0 ± NA-3.0 ± NA
Combined PI:Change follow-up (n=48, 47)0.5 ± 2.340.2 ± 2.56
Combined Pain Interference(Pf):Baseline(n=244,243)3.0 ± 2.642.8 ± 2.52
Combined Pf: Change at C2 D1 (n=191, 194)-0.5 ± 2.44-0.4 ± 1.97
Combined Pf: Change at C3 D1 (n=136,143)-0.8 ± 2.99-0.5 ± 2.01
Combined Pf: Change at C4 D1 (n=98,109)-0.4 ± 2.62-0.7 ± 2.12
Combined Pf: Change at C5 D1 (n=66, 62)-0.6 ± 3.18-0.6 ± 2.07
Combined Pf: Change at C6 D1 (n=41, 41)-0.4 ± 2.92-0.6 ± 2.38
Combined Pf: Change at C7 D1 (n=25, 25)0.3 ± 2.32-0.5 ± 2.10
Combined Pf: Change at C8 D1 (n=12, 12)0.4 ± 1.84-0.9 ± 2.15
Combined Pf: Change at C9 D1 (n=6, 6)-1.4 ± 2.690.7 ± 2.86
Combined Pf: Change at C10 D1 (n=2, 3)-0.5 ± 0.712.1 ± 2.90
Combined Pf: Change at C11 D1 (n=1, 1)0.0 ± NA1.9 ± NA
Combined Pf: Change at C12 D1 (n=1, 0)0.0 ± NANA ± NA
Combined Pf: Change at C13 D1 (n=1, 1)0.0 ± NA-2.7 ± NA
Combined Pf: Change at follow-up (n=47, 45)0.7 ± 3.550.3 ± 3.40
SecondaryChange From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Reported as:
Mean · Units on a scale
Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile
Units on a scaleAxitinib + GemcitabinePlacebo + Gemcitabine
Baseline (n=289, 290)0.665 ± 0.27090.690 ± 0.2479
Change at C2 D1 (n=231, 240)0.050 ± 0.26990.020 ± 0.2033
Change at C3 D1 (n=171, 178)0.053 ± 0.25280.028 ± 0.2362
Change at C4 D1 (n=128, 131)0.010 ± 0.27300.050 ± 0.2209
Change at C5 D1 (n=94, 80)0.010 ± 0.28890.044 ± 0.2092
Change at C6 D1 (n=57, 57)0.001 ± 0.24890.058 ± 0.2294
Change at C7 D1 (n=37, 36)0.049 ± 0.18910.075 ± 0.1838
Change at C8 D1 (n=17, 20)-0.021 ± 0.23660.071 ± 0.2188
Change at C9 D1 (n=9, 9)0.049 ± 0.18780.121 ± 0.3006
Change at C10 D1 (n=3, 4)0.181 ± 0.22060.208 ± 0.3034
Change at C11 D1 (n=1, 1)0.000 ± NA0.058 ± NA
Change at C12 D1 (n=1, 0)0.000 ± NANA ± NA
Change at C13 D1 (n=1, 1)0.000 ± NA0.470 ± NA
Change at follow-up (n=65, 73)-0.148 ± 0.3637-0.080 ± 0.3243
SecondaryChange From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Reported as:
Mean · Millimeter (mm)
Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score
Millimeter (mm)Axitinib + GemcitabinePlacebo + Gemcitabine
Baseline (n= 277, 281)60.6 ± 23.6762.6 ± 23.09
Change at Cycle 2 Day 1 (n= 223, 226)1.0 ± 19.64-0.4 ± 20.42
Change at Cycle 3 Day 1 (n= 161, 171)2.6 ± 22.301.1 ± 20.25
Change at Cycle 4 Day 1 (n=122, 128)0.5 ± 22.383.2 ± 19.81
Change at Cycle 5 Day 1 (n= 90, 79)-0.3 ± 22.831.9 ± 19.40
Change at Cycle 6 Day 1 (n= 56, 56)1.0 ± 24.633.7 ± 21.84
Change at Cycle 7 Day 1 (n= 36, 35)2.6 ± 25.824.1 ± 22.52
Change at Cycle 8 Day 1 (n= 16, 19)3.8 ± 23.219.6 ± 28.55
Change at Cycle 9 Day 1 (n= 9, 9)22.2 ± 24.937.7 ± 20.00
Change at Cycle 10 Day 1 (n= 3, 4)20.0 ± 26.466.3 ± 24.62
Change at Cycle 11 Day 1 (n= 1, 1)0.0 ± NA30.0 ± NA
Change at Cycle 12 Day 1 (n= 1, 0)0.0 ± NANA ± NA
Change at Cycle 13 Day 1 (n= 1, 1)0.0 ± NA36.0 ± NA
Change at follow-up (n= 62, 68)-6.3 ± 24.07-4.8 ± 22.79
SecondaryPopulation Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 23 months
Reported as:
Mean · ng/mL

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Gemcitabine—108/304 (35.5%)276/304 (90.8%)
Placebo + Gemcitabine—102/309 (33%)276/309 (89.3%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
EventAxitinib + GemcitabinePlacebo + Gemcitabine
Disease progressionGeneral disorders9/30415/309
Abdominal painGastrointestinal disorders14/30410/309
PyrexiaGeneral disorders13/3045/309
VomitingGastrointestinal disorders9/30411/309
AstheniaGeneral disorders8/3042/309
NauseaGastrointestinal disorders7/3043/309
CholangitisHepatobiliary disorders7/3043/309
Decreased appetiteMetabolism and nutrition disorders7/3044/309
JaundiceHepatobiliary disorders6/3044/309
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/3046/309
Most frequent other events
Showing 10 of 543
Most frequent other events
EventAxitinib + GemcitabinePlacebo + Gemcitabine
NauseaGastrointestinal disorders138/304112/309
FatigueGeneral disorders125/304113/309
Decreased appetiteMetabolism and nutrition disorders115/30487/309
DiarrhoeaGastrointestinal disorders96/30464/309
VomitingGastrointestinal disorders91/30495/309
ConstipationGastrointestinal disorders88/30491/309
HypertensionVascular disorders84/30426/309
NeutropeniaBlood and lymphatic system disorders73/30453/309
DysphoniaRespiratory, thoracic and mediastinal disorders68/30412/309
Abdominal painGastrointestinal disorders54/30452/309

Baseline characteristics

Age, Customized
Age, Customized(Participants)Axitinib + GemcitabinePlacebo + GemcitabineTotal
Less than 65 years203179382
Greater than or equal to 65 years111137248
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + GemcitabinePlacebo + GemcitabineTotal
Female123128251
Male191188379
08

Study locations

205 sites
  • Pfizer Investigational Site
    Antioch, California 94531, United States
  • Pfizer Investigational Site
    Corona, California 92878, United States
  • Pfizer Investigational Site
    Glendora, California 91741, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093, United States
  • Pfizer Investigational Site
    LaVerne, California 91750, United States
  • Pfizer Investigational Site
    Pamona, California 91105, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    Pleasent Hill, California 94523, United States
  • Pfizer Investigational Site
    Pomona, California 91767, United States
  • Pfizer Investigational Site
    Rancho Cucamonga, California 91730, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    Redlands, California 92374, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92161, United States
  • Pfizer Investigational Site
    San Leandro, California 94578, United States
  • Pfizer Investigational Site
    West Covina, California 91790, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33028, United States
  • Pfizer Investigational Site
    Stuart, Florida 34994, United States
  • Pfizer Investigational Site
    Tampa, Florida 33612, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Augusta, Georgia 30901, United States
  • Pfizer Investigational Site
    Augusta, Georgia 30909, United States
  • Pfizer Investigational Site
    Coeur D'Alene, Idaho 83814, United States
  • Pfizer Investigational Site
    Alton, Illinois 62002, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Beech Grove, Indiana 46107, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46237, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46260, United States
  • Pfizer Investigational Site
    Jeffersonville, Indiana 47130, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40207, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40241, United States
  • Pfizer Investigational Site
    Shelbyville, Kentucky 40065, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70806, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Pfizer Investigational Site
    Annapolis, Maryland 21401, United States
  • Pfizer Investigational Site
    Burlington, Massachusetts 01805, United States
  • Pfizer Investigational Site
    Peabody, Massachusetts 01960, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49007, United States
  • Pfizer Investigational Site
    Columbus, Mississippi 39705, United States
  • Pfizer Investigational Site
    Corinth, Mississippi 38834, United States
  • Pfizer Investigational Site
    Southaven, Mississippi 38671, United States
  • Pfizer Investigational Site
    Tupelo, Mississippi 38801, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63136, United States
  • Pfizer Investigational Site
    Billings, Montana 59101, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68510, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89135, United States
  • Pfizer Investigational Site
    Mineola, New York 11501, United States
  • Pfizer Investigational Site
    Syracuse, New York 13210, United States
  • Pfizer Investigational Site
    Canton, Ohio 44718, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43214, United States
  • Pfizer Investigational Site
    Sylvania, Ohio 43560, United States
  • Pfizer Investigational Site
    Portland, Oregon 97227-1191, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37916, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37934, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38104, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38120, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Austin, Texas 78745, United States
  • Pfizer Investigational Site
    Austin, Texas 78758, United States
  • Pfizer Investigational Site
    Austin, Texas 78759, United States
  • Pfizer Investigational Site
    Dallas, Texas 75325-7786, United States
  • Pfizer Investigational Site
    Dallas, Texas 75325, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390, United States
  • Pfizer Investigational Site
    Round Rock, Texas 78664, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84112, United States
  • Pfizer Investigational Site
    Lynchburg, Virginia 24501, United States
  • Pfizer Investigational Site
    Everett, Washington 98201, United States
  • Pfizer Investigational Site
    Federal Way, Washington 98003, United States
  • Pfizer Investigational Site
    Kennewick, Washington 99336, United States
  • Pfizer Investigational Site
    Lakewood, Washington 98499, United States
  • Pfizer Investigational Site
    Puyallup, Washington 98372, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Bahia Blanca, Buenos Aires B8000FJI, Argentina
  • Pfizer Investigational Site
    La Plata, Buenos Aires B1900AVG, Argentina
  • Pfizer Investigational Site
    Ciudad Autonoma de Buenos Aires, C1426ANZ, Argentina
  • Pfizer Investigational Site
    Santa Fe, 3000, Argentina
  • Pfizer Investigational Site
    St. Leonards, New South Wales 2065, Australia
  • Pfizer Investigational Site
    Wollongong, New South Wales 2500, Australia
  • Pfizer Investigational Site
    Clayton, Victoria 3168, Australia
  • Pfizer Investigational Site
    East Bentleigh, Victoria 3165, Australia
  • Pfizer Investigational Site
    Salzburg, A-5020, Austria
  • Pfizer Investigational Site
    Wels, A-4600, Austria
  • Pfizer Investigational Site
    Wien, 1030, Austria
  • Pfizer Investigational Site
    Wien, 1090, Austria
  • Pfizer Investigational Site
    Wien, A-1090, Austria
  • Pfizer Investigational Site
    Brussel, 1090, Belgium
  • Pfizer Investigational Site
    Bruxelles, 1000, Belgium
  • Pfizer Investigational Site
    Bruxelles, 1200, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Pfizer Investigational Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8R 6V5, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R2H 2A6, Canada

Showing the first 100 of 205 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar;12(3):256-62. doi: 10.1016/S1470-2045(11)70004-3. PubMed 21306953 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jan 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 3 years 6 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2007
First posted
May 9, 2007
Start
Jul 2007
Primary completionActual
Jan 2009
CompletionActual
Nov 2010
Results delay requested
Feb 11, 2010
Results first posted
Jul 16, 2012
Last update
Jul 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00471146
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 9, 2007
Start date
Jul 2007
Primary completion
Jan 2009
Completion
Nov 2010
Results posted
Jul 16, 2012
Last update
Jul 16, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion